Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 3/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644116 | 0.82 | MAPT (0.54) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL22644103 | 0.81 | MAPT (0.56) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL22644106 | 0.80 | MAPT (0.61) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL21366050 | 0.78 | MAPT (0.60) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL21366326 | 0.77 | MAPT (0.58) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL21366075 | 0.77 | MAPT (0.58) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL17537657 | 0.76 | KMT2A (0.63) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL21366458 | 0.75 | MEN1 (0.62) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL21366245 | 0.75 | MAPT (0.56) | MAPTMEN1KMT2AAHRNR1I2 | |
| SCHEMBL21366105 | 0.74 | MAPT (0.55) | MAPTMEN1KMT2AAHRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210179604-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200354353-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179604-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885 |
| US-11459322-B2 | Indole compounds and their use | IDO1, IDO2, INMT | MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885 |
| US-20200354353-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885 |
| US-20230054194-A1 | Methods of Treating Cancer | TP53, MSH2, PDCD1 | MAPT 3515/4885MEN1 1911/4885KMT2A 1118/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.